Drug intelligence / Profile preview

ICA3001

Development stage: Preclinical
Lead developer: iCamuno Biotherapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

ICA3001 is an investigational cell therapy product based on induced pluripotent stem cells (iPSC), developed by Suzhou Aikailiyuan Biotechnology. It is in preclinical development for the treatment of neoplasms (cancers). The specific mechanism of action, molecular targets, and cancer subtypes addressed have not been publicly disclosed as of June 2025. The drug represents a novel approach leveraging iPSC technology for oncology applications[1][2][3].

Other names: ICA-3001ICA3001ICA 3001

Beyond the preview

Go deeper on ICA3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICA3001.

Explore the full profile